The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
A.M.M. Eggermont(Praxis für Hämatologie und Onkologie), D. J. Ruiter(Radboud University Nijmegen), Ulrich Keilholz(German Cancer Research Center), Alberto Testori(IRCCS Humanitas Research Hospital), Matthew A. Cook(University of Virginia), D. Liénard
PubMed
October 1, 2001
Cited by 18
Related Papers
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
|The Lancet|2008|644
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|621
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
|The Oncologist|2011|579